Molecular genetic tests use DNA or RNA as the analyte of interest. The type of sample required is usually whole blood or buccal cells. Certain tests require specific tissue because RNA is not ...

Molecular profiling and genetic testing have revolutionised lung cancer treatment, says a doctor. They have enabled targeted ...

GeneDx CEO Katherine Stueland likes the potential of newborn testing, but she says her Stamford, Connecticut, company is still studying the idea. A potential challenge: Insurers would have to embrace ...

epigenome and transcriptome using single-molecule chromatin fiber sequencing and multiplexed arrays isoform sequencing identifies the genetic and molecular basis of an undiagnosed Mendelian ...

In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...

Going forward, Exact Sciences is launching Oncodetect, a molecular residual disease test, and Cancerguard, a multi-cancer screening test. Fulgent Testing (FLGT 0.31%) is a genetic testing company ...

The test employs a combination of tumour-agnostic next-generation sequencing and personalised tumour-informed droplet PCR assays.

A patient found to carry a BRCA1 pathogenic variant is not referred to a certified genetic counselor in her health system.

For example, in prenatal screening for CF, the client's history is important in determining which test is appropriate. Molecular genetic test results are interpreted within the context of the ...

Myriad Genetics announces USPTO grants two new patents for its molecular residual disease assay: Salt Lake City Friday, February 7, 2025, 13:00 Hrs [IST] Myriad Genetics, Inc., a ...